Biosynth, a supplier of critical materials to the life science industry, is pleased to announce the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply.
Dr. Urs Spitz, CEO and President of Biosynth, commented, “We are very excited for Pepceuticals to be joining Biosynth. The Pepceuticals team has great expertise in optimizing the production of peptides and working at GMP and larger scales, making it a natural fit for Biosynth as we round out our peptide offering."
Ehab Alramahy, Senior Vice President, Head of Peptide Division, added “The acquisition of Pepceuticals into the Biosynth family strengthens our position in the peptide field. As we've built the peptide division, our goal has always been to offer a seamless, comprehensive service to our customers. The acquisition represents an important step which allows us to extend our support to clinical trials and commercial supply.”
“Joining the Biosynth Group marks the start of an exciting chapter for our team,” Dr. Kamal Badiani, Managing Director of Pepceuticals, states, “We look forward to working together, combining our expertise and enhancing our offering to our customers. We are excited to join Biosynth and provide leading peptide manufacturing services.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!